drugset / Trial / NCT06055166
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is a prospective, multi-cohort, single-centre, phase II clinical trial designed to initially explore the efficacy and safety of sequential fluzoparib with chemoradiotherapy in pan-solid tumours. The study is designed for patients with untreated surgically resectable rectal cancer and untreated locally advanced unresectable non-small cell lung cancer, oesophageal squamous cancer, and cervical cancer.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2024-11-30
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Fluzoparib | Small molecule | — | — |
Indications
No indication recorded.